Inactive Instrument

Cascadian Therapeutics Inc (USA) Stock

Equities

Duration

Period

Style

Cascadian Therapeutics Announces 2018 Outlook and Recent Progress	18-01-04	GL
Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency	18-01-02	GL
Cascadian Therapeutics Added to the Nasdaq Biotechnology Index	17-12-13	GL
Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer	17-12-07	GL
Cascadian Therapeutics Reports Third Quarter 2017 Financial Results	17-11-08	GL

Sector

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.34%	103B
REGENERON PHARMACEUTICALS, INC.	+2.31%	96.56B
ARGENX SE	+2.01%	22.61B
BIONTECH SE	-16.72%	21.18B
GENMAB A/S	-3.81%	19.07B
WUXI APPTEC CO., LTD.	-41.75%	16.53B
BEIGENE, LTD.	-23.26%	14.46B
NEUROCRINE BIOSCIENCES, INC.	-0.02%	13.25B
SAREPTA THERAPEUTICS, INC.	+22.69%	11.1B